KALA BIO Announces Reverse Stock Split
The split will not change stockholders' percentage equity interests, except where fractional shares result.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
KALA BIO (NASDAQ: KALA) plans a 1-for-30 reverse stock split effective at 4:05 p.m. on November 13, 2026.
Split-adjusted trading will begin on the Nasdaq Capital Market on November 16, 2026, under the unchanged symbol KALA. The split will reduce outstanding common shares from 19,339,786 to approximately 644,659. Proportional adjustments will apply to shares issuable under equity awards, warrants and other convertible securities, and their exercise or conversion prices. No fractional shares will be issued; affected holders will receive cash based on the November 12, 2026 closing price on the Nasdaq Capital Market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Common Stock Will Begin Trading on a Split-Adjusted Basis on November 16, 2026
Arlington, Massachusetts--(Newsfile Corp. - November 12, 2026) - KALA BIO, Inc. (NASDAQ: KALA) ("KALA BIO" or the "Company"), today announced that it intends to effect a reverse stock split of its common stock, par value
At a special meeting of stockholders, held on November 3, 2026, the Company's stockholders granted the Company's Board of Directors the discretion to effect a reverse stock split of the Company's common stock through an amendment to its Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-300, with such ratio to be determined by the Company's Board of Directors.
At the effective time of the reverse stock split, every thirty (30) shares of the Company's issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-30 reverse stock split. It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares will be issued. Stockholders that would hold fractional shares as a result of the Reverse Stock Split are entitled to receive a cash payment in lieu of said fractional shares based on the closing price on the Nasdaq Capital Market on November 12, 2026. The reverse stock split will reduce the number of shares of the Company's common stock outstanding from 19,339,786 shares to approximately 644,659 shares. Proportional adjustments will be made to the number of shares of the Company's common stock issuable upon exercise or conversion of the Company's equity awards, warrants and other convertible securities, as well as the applicable exercise or conversion price thereof. Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions to the Company's transfer agent, Equiniti Trust Company, LLC, at (929) 469-2386.
ABOUT KALA BIO (NASDAQ: KALA)
KALA BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company's dual strategy combines a proprietary biologics pipeline-including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates-with a scalable AI platform-as-a-service business that deploys secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments. Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company's focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector. Kala believes the future of biomedical innovation is in agentic systems.
For more information, visit www.kalarx.com and www.Researgency.ai
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: the effect that the reverse stock split may have on the price of the Company's common stock; the Company's ability to maintain its listing on the Nasdaq Capital Market; and other risks detailed in the "Risk Factors" section of the Company's Annual Report on Form 10-K as they may be revised in the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Contact:
Avi Minkowitz
Chief Executive Officer,
KALA BIO, Inc.
am@kalarx.com
www.kalarx.com | www.Researgency.ai
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323680
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does KALA BIO's reverse stock split take effect, and what is the ratio?
KALA BIO's 1-for-30 reverse stock split takes effect at 4:05 p.m. on November 13, 2026. Split-adjusted trading begins on November 16, 2026, on the Nasdaq Capital Market under KALA.